1. In Vivo
  2. >>Business Strategy

The Quintessential Specialty Pharma, Valeant Embodies PE Tenets

Even as private equity firms reach into specialty pharma niche opportunities for deals, specialty pharma companies are evolving, as well. Valeant Pharmaceuticals is a very visible example of one kind of specialty pharma model, which is based as much upon sophisticated financial engineering as product growth.

Perhaps more than any other biopharma in recent years, Valeant Pharmaceuticals International Inc. has brought private equity (PE) tactics to bear as a strategic acquirer, explicitly relying solely on acquisitions rather than R&D to create exponential growth. It has emerged as a big cap in recent years, providing a vision centered on sophisticated business, rather than research, expertise. (SeeAlso see "Acquisitive Valeant Sheds Staff As It Closes Bausch & Lomb Deal" - Pink Sheet, 29 July, 2013..)

Since 2010, when it entered into a reverse merger with Biovail, Valeant has embarked on more than 25 company and...

More from Business Strategy

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By David Wild

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

AI In Drug Discovery: The Patent Implications

 
• By David Wild

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.

Is Advanced AI Revolutionizing Sales Enablement In Pharma?

 
• By Marina Hickson

Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.

More from In Vivo